Insilico Medicine to present at Leveraging Intelligent Tech for Drug Development
Credit: Insilico Medicine
Wednesday, September 30, 2020 – Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Live Leveraging Intelligent Tech for Drug Development Forum on September 30, 2020.
AI, automation and data integration are condensing the timeline from discovery to development and solving biological problems. On September 30th, leaders from biotech and pharma will discuss specific examples of how these technological advancements are reshaping the drug development landscape.
While technology continues to revolutionize biotech, pharmaceutical companies are investing heavily in modernizing internally to embrace and embed these innovations throughout their organizational structure and culture. On the clinical trial front, not only are sponsors pressed to have remote and decentralized designs for their trial models due to the ongoing COVID19 pandemic, but regulators have openly expressed their willingness to consider creative new ideas for trial design, including wearable technology for remote data capture. Meanwhile in the workforce, competition is fierce to recruit and maintain the best talent and to understand how the role of the scientist is evolving to embrace the future of tech-enabled biopharma.
“We are thrilled to have CEO Alex Zhavoronkov address stakeholders at the upcoming digital forum on Leveraging Intelligent Tech for Drug Development on September 30th, hosted by Unite Life Sciences. Insilco Medicine’s work in the use of AI in drug discovery for Sars-CoV-2 and the ongoing COVID19 Global Pandemic offers remarkable insight to participants in the forum, which convenes senior decision makers, investors, and innovators in pharma, biotech and venture capital to examine real-case scenarios for accelerating drug discovery and modernizing clinical trials with data & automation. Unite Life Sciences is the dedicated life science division of IQPC US. Their digital content & forums provide a platform to drive stakeholder engagement, collaboration, and transformational change in biopharma.” said Nicole Hayes, Managing Director, Unite Life Sciences.
“I am very happy to present at Leveraging Intelligent Tech for Drug Development – a great event to gain insight on how industry can successfully align innovation in science, design, regulatory process and patient-centricity.” said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine.
For further information, images or interviews, please contact: [email protected]
About Insilico Medicine
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.